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Abstract Ceftaroline is a broad-spectrum antibiotic with ac-
tivity against methicillin-resistant Staphylococcus aureus
(MRSA) strains. Ceftaroline susceptibility of an MRSA set
archived between 1994 and 2003 in the Geneva University
Hospitals detected a high percentage (66 %) of ceftaroline
resistance in clonotypes ST228 and ST247 and correlatedwith
mutations in PBP2a. The ceftaroline mechanism of action is
based on the inhibition of PBP2a; thus, the identification of
PBP2a mutations of recently circulating clonotypes in our
institution was investigated. We analyzed ceftaroline suscep-
tibility inMRSA isolates (2013 and 2014) and established that
resistant strains correlated with PBP2a mutations and specific
clonotypes. Ninety-six MRSA strains were analyzed from in-
dependent patients and were isolated from blood cultures
(23 %), deep infections (38.5 %), and superficial (skin or
wound) infections (38.5 %). This sample showed a ceftaroline
minimum inhibitory concentration (MIC) range between 0.25
and 2 μg/ml and disk diameters ranging from 10 to 30 mm,
with a majority of strains showing diameters ≥20 mm. Based
on the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoints, 76 % (73/96) of isolates
showed susceptibility to ceftaroline. Nevertheless, we still ob-
served 24 % (23/96) of resistant isolates (MIC = 2 μg/ml). All
resistant isolates were assigned to clonotype ST228 and car-
ried the N146K mutation in PBP2a. Only two ST228 isolates
showed ceftaroline susceptibility. The decreasing percentage
of ceftaroline-resistant isolates in our hospital can be ex-
plained by the decline of ST228 clonotype circulating in our
hospital since 2008. We present evidence that ceftaroline is
active against recent MRSA strains from our hospital; howev-
er, the presence of PBP2a variants in particular clonotypes
may affect ceftaroline efficacy.
Introduction
Infections caused by methicillin-resistant Staphylococcus
aureus (MRSA) are a major worldwide health problem.
MRSA, initially identified as a nosocomial pathogen, is
now responsible for both hospital- and community-
acquired infections [1]. MRSA treatment options include
glycopeptides and combination regimens [2], as well as
new agents like daptomycin and last-generation cephalo-
sporins (ceftobiprole and ceftaroline). Despite the avail-
ability of several antimicrobials, resistance to a particular
antibiotic has repeatedly brought complications for the
successful treatment of MRSA infections.
β-Lactam antibiotics were first developed to inhibit
penicillin-binding proteins (PBPs) that catalyze cell wall bio-
synthesis. However, soon after their introduction, the efficacy
of β-lactams was altered by S. aureus strains producing a β-
lactamase enzyme or by horizontal acquisition of mecA,
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encoding the penicillin-binding protein PBP2a. PBP2a is not
inhibited by β-lactams and can consequently catalyze DD-
t r anspep t ida t ion and coope ra t e wi th the PBP2
transglycosylase in peptidoglycan biosynthesis [3, 4].
Ceftaroline is a novelβ-lactam broad-spectrum cephalospo-
rin, capable of inhibiting PBP2a. Its anti-MRSA activity shows
an MIC90 of around 1–2 μg/ml and has been approved for the
treatment of complicated skin and soft tissue infections and
community-acquired pneumonia [5–7]. Several studies have
shown decreased susceptibility of MRSA to ceftaroline
(EUCAST MIC values of > 1 μg/ml or CLSI MIC ≥ 4 μg/ml)
in sporadic cases and limited to specific sequence types (STs)
[8–12]. Recently, high-level ceftaroline resistance
(MIC > 32 μg/ml) was observed during sustained MRSA bac-
teremia treated with ceftaroline [13]. Low-level resistance to
ceftaroline is associated with mutations in PBP2a found in both
the allosteric domain (N146K, E150K, N204K, E239K,
G246E) or the transpeptidase domain (H351N, Y446N,
E447) [3, 8, 13–17].
While high-level ceftaroline resistance can be explained by
mutations in the transpeptidase domain that alter the active site
geometry, low-level resistance associated with mutations
within the allosteric site was explained by a novel allosteric
modulation of the active site [15, 18–20]. Ceftaroline binds to
the PBP2a allosteric site at therapeutic concentrations and
triggers the opening and acylation of the active site by a sec-
ond ceftaroline molecule [7, 20]. Mutations within the PBP2a
allosteric domain alter the triggering mechanism and possibly
affect protein–protein interactions needed for peptidoglycan
biosynthesis [7, 14, 19, 21–23]. Additional factors contribut-
ing to ceftaroline resistance remain to be analyzed [24].
Surprisingly, reduced susceptibility has been described in clin-
ical S. aureus isolates predating the commercial introduction
of ceftaroline [8, 25] and in countries where ceftaroline is not
commercially available [17].
Our previous study showed that decreased ceftaroline sus-
ceptibility was linked to circulating clonotypes ST228 and
ST247 carrying mutations in the allosteric domain of PBP2a
[8]. Since there has been a major change in MRSA epidemiol-
ogy at our institution during the last 5 years [26], the analysis of
ceftaroline susceptibility and mutations in PBP2a of contem-
porary circulating MRSA isolates in our institution was under-
taken. MRSA isolates from 2013 to 2014 causing either soft
tissue infections or bloodstream infections were examined.
Materials and methods
Bacterial strains and susceptibility testing
A collection of 96 independent MRSA strains archived from
2013 to 2014 and representing bloodstream, deep tissue, and
superficial infection samples were tested. The methicillin-
susceptible S. aureus (MSSA) and ceftaroline-susceptible
strain ATCC29213, MIC 0.25 μg/ml, was used as the
EUCAST standard quality control strain. Standardized proce-
dures were as previously described [8] and determined accord-
ing to EUCAST recommendations.
mecA gene sequencing
Genomic DNA (gDNA) was prepared as previously described
[27] and mecA was amplified by polymerase chain reaction
(PCR) (3 Kb) using specific primers: seq_meclocus-F 5′
TAAGGGAGAAGTAACAGCAC 3′ and seq_meclocus-R
5′ ATCGCCCAAAGCTTCTTTAG 3′. PCR fragments were
sequenced using appropriate primers within mecA. Sequence
alignments were performed using Clustal Omega and mecA
reference sequences from N315 (SA0038) and COL
(SACOL0033).
MLVA genotyping
Each tested MRSAwas analyzed by a rapid genotyping assay
(MLVA) [28]. The genotype of each strain was deduced by
comparison with profiles obtained with well-characterized
standard isolates.
Results
Determination of ceftaroline susceptibility in the MRSA
strain collection (2013–2014) of Geneva University
Hospitals
A previous study from our laboratory found a high rate of
ceftaroline non-susceptibility in a collection of MRSA strains
recovered from bloodstream infections during the period
1994–2003 [8]. To determine if ceftaroline resistance was still
prevalent in our institution, we examined the ceftaroline sus-
ceptibility of 96MRSA isolates archived in 2013–2014, using
both disk diffusion and microdilution MIC methods. The
specimen sources included 37 deep wound infections
(38.5 %), 37 superficial (skin or wound) infections (38.5 %),
and 22 bloodstream infection (23 %) isolates. Using
ceftaroline 5 μg disks, our strain collection showed mean di-
ameters ranging from 10 to 30 mm (Table 1), with a majority
(79 %) of isolates (76/96) showing diameters ≥20 mm, but
21 % of isolates (20/96) showing a diameter <20 mm in at
least three independent measurements (EUCAST breakpoints
S ≥ 20 and R < 20 mm).
MIC determinations are required to confirm the suscepti-
bility of strains showing disk diameters between 19 and
21mm, according to the EUCAST guidelines. All strains were
tested by the microdilution assay by three independent mea-
surements (Table 1). For all strains tested, the disk diffusion
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Table 1 Ceftaroline minimum
inhibitory concentration (MIC)




Hospitals 2013–2014) tested by
microdilution and disk diffusion
assays





24 h 48 h
1 2013 2 2 20 R 228
2 2013 1 1 21 S 105
3 2013 0.5 0.5 24 S 8
4 2013 1 1 22 S 105
5 2013 2 2 18 R 228
6 2013 2 4 17 R 228
7 2013 1 1 21 S 105
8 2013 0.25 0.5 25 S 8
9 2013 0.5 0.5 22 S 105
10 2013 1 1 21 S 105
11 2013 0.5 0.5 22 S 8
12 2013 1 1 22 S 228
13 2013 0.5 0.5 22 S 30
14 2013 1 1 21 S 5
15 2013 2 2 16 R 228
16 2013 0.25 0.5 25 S 80
17 2013 0.5 0.5 24 S 8
18 2013 0.5 0.5 25 S 8
19 2013 0.5 0.5 23 S 8
20 2013 0.5 0.5 24 S 8
21 2013 0.5 0.5 22 S 80
22 2013 0.5 0.5 24 S 8
23 2013 2 4 17 R 228
24 2013 2 4 17 R 228
25 2013 0.25 0.5 23 S NT
26 2013 0.5 1 22 S 8
27 2013 2 4 18 R 228
28 2013 2 2 17 R 228
29 2013 1 1 21 S 105
30 2013 0.5 0.5 23 S 8
31 2013 0.5 1 26 S 105
32 2013 2 4 18 R 228
33 2013 0.5 0.5 25 S 125
34 2013 0.5 0.5 23 S 105
35 2013 0.5 1 21 S 80
36 2013 0.5 0.5 22 S 108
37 2013 0.5 1 24 S 8
38 2013 0.5 1 23 S 8
39 2013 2 2 19 R 228
40 2013 0.5 0.5 22 S 5
41 2013 0.5 0.5 23 S 8
42 2013 2 4 17 R 228
43 2013 2 4 17 R 228
44 2013 2 2 18 R 228
45 2013 0.5 0.5 22 S 30
46 2013 2 4 18 R 228
47 2013 2 4 19 R 228
48 2013 0.5 0.5 24 S NT
49 2013 0.5 0.5 23 S 105
50 2013 1 1 22 S 105
51 2013 2 4 16 R 228
52 2013 0.5 0.5 23 S 30
53 2013 0.5 0.5 22 S 30
54 2013 0.5 0.5 23 S 8
55 2013 0.5 0.5 24 S 30
56 2013 0.5 0.5 23 S 8
57 2013 0.5 0.5 25 S 8
58 2013 2 4 17 R 228
59 2013 0.5 0.5 24 S 8
60 2013 2 4 10 R 228
61 2013 0.5 0.5 22 S 105
62 2013 0.5 0.5 24 S 8
63 2013 0.5 0.5 28 S NT
64 2013 0.5 0.5 25 S NT
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results were in agreement with the MIC microdilution assays.
The isolates with diameters 19 or 20mmwere all confirmed to
be resistant byMICmicrodilution, while those showing diam-
eters of 21 mm were all confirmed as susceptible.
Overall, this strain set showed a ceftaroline MIC range
between 0.25 and 2 μg/ml and 0.25 and 4 μg/ml at 24 and
48 h of incubation, respectively (Table 1). The frequency
of MIC distribution for ceftaroline was 8.3, 52.1, 15.6, and
24 % for isolates showing an MIC of 0.25, 0.5, 1, and
2 μg/ml, respectively. A large proportion (73/96; 76 %)
of isolates showed susceptibility to ceftaroline (EUCAST
microdilution breakpoints S ≤ 1 and R > 1 μg/ml), with the
majority (50/96) showing an MIC value of 0.5 μg/ml.
Nevertheless, we still observed an elevated proportion
(23/96; 24 %) of isolates showing an MIC of 2 μg/ml (at
24 h), thus considered resistant (Table 1).
PBP2a allosteric site mutations correlate with reduced
ceftaroline susceptibility
The previously published ceftaroline-resistant strains from our
hospital (the 1994–2003 collection) principally belong to
clonotypes ST228 and ST247 [8]. The most plausible hypoth-
esis to explain the presence of resistant strains in our 2013–
2014 collection is that they represent bacterial clones belong-
ing to the ST228 or ST247 typing family and carrying PBP2a
mutations [8, 25]. Accordingly, MRSA isolates were subject-
ed to MLST determination and PBP2a (mecA) sequence anal-
ysis. Isolates were first subjected to multiple-locus variable-
number tandem repeat analysis (MLVA), a rapid genotyping
assay allowing assessment of genomic content and assign-
ment of MLST type [28, 29]. The STs of all strains are pre-
sented in Table 1.
Table 1 (continued)





24 h 48 h
65 2013 0.5 0.5 24 S 8
66 2013 2 4 14 R 228
67 2013 0.5 0.5 23 S 80
68 2013 0.5 0.5 23 S 8
69 2013 0.5 0.5 22 S 30
70 2013 0.5 1 23 S 5
71 2013 0.25 0.5 25 S 5
72 2013 0.5 1 23 S 8
73 2014 0.25 0.5 26 S 30
74 2014 2 4 20 R 228
75 2014 1 2 22 S 228
76 2014 1 1 22 S 80
77 2014 2 4 18 R 228
78 2014 0.5 0.5 23 S 8
79 2014 0.25 0.5 30 S 8
80 2014 2 2 19 R 228
81 2014 2 4 20 R 228
82 2014 0.5 0.5 23 S 30
83 2014 0.5 0.5 23 S 105
84 2014 0.5 0.5 25 S 125
85 2014 0.5 0.5 24 S 8
86 2014 1 1 23 S 105
87 2014 0.5 0.5 27 S 105
88 2013 0.5 0.5 24 S 105
89 2013 1 1 23 S 105
90 2013 1 2 21 S 125
91 2013 0.25 0.5 26 S 30
92 2013 1 1 23 S 5
93 2013 0.5 0.5 25 S 5
94 2013 1 1 25 S 105
95 2014 0.25 0.5 25 S 1
96 2013 0.5 0.5 24 S 1
aATCC29213 0.25 0.5 29 S
If the diameter is between 19 and 21 mm, an MIC determination will confirm susceptibility
NT non-typable strain
aMIC values for ATCC29213 are within the EUCAST-approved ranges for ceftaroline
b EUCAST microdilution ceftaroline susceptibility breakpoint S ≤ 1; R > 1
c EUCAST ceftaroline disk susceptibility breakpoints S ≥ 20 mm; R < 20 mm
d Susceptibility phenotype based on EUCAST recommendation
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PBP2a (mecA) sequence analysis was next performed
(Table 2). PBP2a sequences from our strain collection were
compared to the previously published Greek strain sequences
and amino acid changes were annotated [16] (Table 2).
Interestingly, and consistent with our hypothesis, all resistant
strains (MIC = 2 μg/ml) were unambiguously assigned to
ST228 and carried the PBP2a N146K mutation. In contrast,
the majority of susceptible strains were all assigned to other
STs (ST1, ST5, ST8, ST30, ST80, ST93, ST105, and ST125).
Of note, two isolates from the 25 ST228 isolates show
ceftaroline susceptibility, but also carry the N146K mutation,
suggesting that this mutation alone might not be sufficient to
Table 2 PBP2a mutation profiles and ST of selected strains
Strain collection Archived date Strain number Strain name ST PBP2a mutations
MIC N146K E150K E239K N240K G246E H351N E447K
aGreece 4981 ST5 1
aGreece 4977 ST239 2 K K K K
aGreece 2008 13101 ST239 4 K K K K N
HUG 2013 1 1437 ST228 2 K
HUG 2013 5 1441 ST228 2 K
HUG 2013 6 1442 ST228 2 K
HUG 2013 7 1443 ST105 1 E
HUG 2013 12 1448 ST228 1 K
HUG 2013 15 1478 ST228 2 K
HUG 2013 21 1484 ST80 0.5 E
HUG 2013 23 1486 ST228 2 K
HUG 2013 24 1487 ST228 2 K
HUG 2013 27 1490 ST228 2 K
HUG 2013 28 1491 ST228 2 K
HUG 2013 32 1495 ST228 2 K
HUG 2013 34 1497 ST105 0.5 E
HUG 2013 37 1500 ST8 0.5
HUG 2013 39 1502 ST228 2 K
HUG 2013 42 1505 ST228 2 K
HUG 2013 43 1506 ST228 2 K
HUG 2013 46 1509 ST228 2 K
HUG 2013 47 1510 ST228 2 K
HUG 2013 51 1514 ST228 2 K
HUG 2013 52 1515 ST30 0.5
HUG 2013 58 1521 ST228 2 K
HUG 2013 59 1522 ST8 0.5
HUG 2013 60 1523 ST228 2 K
HUG 2013 66 1529 ST228 2 K
HUG 2013 69 1532 ST30 0.5
HUG 2014 74 1537 ST228 2 K
HUG 2014 75 1538 ST228 1 K
HUG 2014 77 1540 ST228 2 K
HUG 2014 80 1543 ST228 2 K
HUG 2014 81 1544 ST228 2 K
HUG 2014 85 1548 ST93 0.5
HUG 2013 90 1553 ST125 1
HUG 2014 95 1558 ST1 0.25
HUG COL ST250 0.25 E
HUG N315 ST5 1
aMendes et al. [16]
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generate ceftaroline resistance in certain circumstances. We
found no other PBP2a mutation in our ceftaroline-resistant
subset. In the ceftaroline-susceptible non-ST228 isolates, the
only PBP2a mutations identified were G246E, found in four
isolates (3 out of 10 mecA sequenced isolates). No G246E
mutation was found in ceftaroline-resistant isolates. This cor-
roborates other studies where no influence on the ceftaroline
susceptibility of this mutation could be associated with
ceftaroline susceptibility profiles [15, 17].
Analysis by sample type
We found ceftaroline-resistant isolates irrespective of the an-
atomical specimen source. The resistance analysis by sample
type reveals that 31.8 % (7/22) of resistant bacteria were iso-
lated from bloodstream infections, 29.7 % (11/37) from deep
infections, and 13.5 % (5/37) from superficial soft tissue/
wound infections. Comparing isolates from superficial infec-
tions with a resistance rate of 13.5 % (5/37) to more invasive
isolates with a resistance rate of 30.5 % (18/59), it might be
inferred that more severe infections are correlated to higher
resistance levels. This result is linked to the higher prevalence
of the ST228 clonotype in deep wounds and bloodstream
infection than in superficial wound specimens. Thus, interest-
ingly, the ST228 hospital-acquired MRSA strain is more fre-
quent in bloodstream infections and deep wound infections
than in community-acquired infections, such as skin and su-
perficial wound infection.
Discussion
Ceftaroline-resistant strains (MIC of 2 μg/ml) were previously
reported and identified in a few clonotypes, including ST228,
ST247, and ST239 [8, 15, 21, 25, 30]. In 2015, we reported a
high percentage (66 %) of ceftaroline resistance in an HUG
bacterial collection first assembled to monitor the emergence
of intermediate glycopeptide resistance [8, 31]. The detection
of ceftaroline resistance among ST228 and ST247 clonotypes
in this archived set prompted us to examine contemporary
MRSA strains from our institution, not biased by prior screen-
ing for intermediate glycopeptide resistance. To what extent
recent ST228 strains display reduced susceptibility to
ceftaroline is an important consideration. Our current study
was further motivated by the fact that ST228 has been endem-
ic since 1998 in our institution, but epidemiological changes
have been observed over the last 5–8 years, with gradual de-
cline of ST228 and replacement by other clonotypes [14, 32]
and, furthermore, by the potential use in clinical practice of
this drug licensed in Switzerland in 2013, but which has not
been used in our hospital to date.
The majority of 2013–2014 MRSA tested in the present
study were found to be susceptible to ceftaroline, showing a
modal MIC of 0.5 μg/ml; however, we observed 24 % resis-
tant isolates (MIC = 2 μg/ml). The percentage of resistance we
report in both studies is subject to cautious interpretation,
since the current strain set may not be representative of an
unbiased sampling since only certain infection types were
analyzed. A second explanation for the lower percentage of
resistant strains in the 2013–2014 compared to the 1994–2003
strain set can be the fact that resistance appears to be strongly
linked with ST228, a clonotype gradually declining in recent
years in our hospital [14, 32].
Although the majority of tested 2013–2014 HUG strains
were found to be susceptible to ceftaroline, it is noteworthy that
all resistant isolates were ST228. Ceftaroline-resistant HUG
ST228 strains are strongly correlated with the N146K mutation
present in the PBP2a allosteric domain. Together with E150K
and E239K, the N146K mutation is one of the most prevalent
mutations in isolates exhibiting a ceftaroline MIC of 2 μg/ml
(including Italy, Hungary, Russia, Spain, and Turkey) [15, 22].
This mutation was previously detected in the ST228 bacterial
strains collected in the interval 1998–2003 in our hospital and
through 2003–2008 in the University Hospital of Lausanne [8].
It is unknown how the South German clone present in our hos-
pital acquired PBP2a mutation. Whether some MRSA
clonotypes, such as ST228, are more amenable to genetic vari-
ation is unknown. Since different missense mutations in PBP2a
are found in several ST228 strains, it is probable that indepen-
dent events occurred to produce this observed PBP2a allotype
variation [8, 15]. ST228, even if diminishing in prevalence over
the last decade in Switzerland, was still responsible for a large
part of the non-community-acquired MRSA infections in the
2013–2014 period, which represents a significant concern.
Mutations in the allosteric domain of PBP2a are thought to
confer low-level ceftaroline resistance by gating the active site
channel [19]. In some cases, genotypic analysis revealed mu-
tation within mecA, but the strain, nevertheless, displayed sus-
ceptibility to ceftaroline [8]. An important consideration is that
proper transcriptional expression of mecA, together with
PBP2a’s posttranslational export, maturation, and positioning,
are crucial steps that govern PBP2a function. Whereas the tran-
scriptional regulation ofmecA is clearly multifactorial [4], only
recently have reports highlighted the importance of additional
factors such as PrsA that affect PBP2a maturation [33, 34].
Taken in this light, the presence of certain mutations within
the PBP2a allosteric domain may not evoke resistance because
of expression constraints. Alternatively, some strains showing a
ceftaroline MIC of 2 μg/ml show wild-type PBP2a sequence,
raising the possibility that additional factors can influence
ceftaroline susceptibility. Notably, mutations in clpX, stp1,
and prsA, as well as the pbp4 promoter, appear to be associated
with ceftaroline resistance [24, 34]. Further genetic studies
must identify genes implicated in ceftaroline resistance and
define how particularly allosteric domain mutations differen-
tially impact the expression of ceftaroline resistance.
348 Eur J Clin Microbiol Infect Dis (2017) 36:343–350
Acknowledgments The authors thank Pierre Vaudaux for his critical
comments.
Compliance with ethical standards
Funding This work was supported by an AstraZeneca investigator-
initiated grant (no. 2793), the Fondation Privée des HUG (AR-S27), the
Swiss National Science Foundation grants (AR 310030-149762, WLK
10030-146540, PF 31003A-153474/1), and a Novartis Foundation grant
(no. 15A040). SH received support from the Innovative Medicines
Initiative Joint Undertaking under the Combatting Bacterial Resistance
in Europe (COMBACTE) grant agreement no. 115523, resources of
which are composed of financial contribution from the EU’s Seventh
Framework Programme (FP7/2007–2013) and the European Federation
of Pharmaceutical Industries and Associations (EFPIA) companies’ in-
kind contribution. The funders had no role in the study design, data
collection, interpretation, or the decision to submit the work for
publication.
Conflict of interest The authors declare no conflict of interest.
Ethical approval Not applicable.
Informed consent Not applicable.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Von Dach E, Diene SM, Fankhauser C, Schrenzel J, Harbarth S,
François P (2016) Comparative genomics of community-associated
methicillin-resistant Staphylococcus aureus shows the emergence
of clone ST8-USA300 in Geneva, Switzerland. J Infect Dis 213(9):
1370–1379. doi:10.1093/infdis/jiv489
2. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B,
Olearo F, Emonet S, Uçkay I (2015) Randomized non-inferiority
trial to compare trimethoprim/sulfamethoxazole plus rifampicin
versus linezolid for the treatment of MRSA infection. J
Antimicrob Chemother 70(1):264–272. doi:10.1093/jac/dku352
3. Harrison EM, Ba X, Blane B, Ellington MJ, Loeffler A, Hill RL,
Holmes MA, Peacock SJ (2016) PBP2a substitutions linked to
ceftaroline resistance in MRSA isolates from the UK. J
Antimicrob Chemother 71(1):268–269. doi:10.1093/jac/dkv317
4. Peacock SJ, Paterson GK (2015) Mechanisms of methicillin resis-
tance in Staphylococcus aureus. Annu Rev Biochem 84:577–601.
doi:10.1146/annurev-biochem-060614-034516
5. Zhong NS, Sun T, Zhuo C, D’Souza G, Lee SH, Lan NH, Chiang
CH, Wilson D, Sun F, Iaconis J, Melnick D (2015) Ceftaroline
fosamil versus ceftriaxone for the treatment of Asian patients with
community-acquired pneumonia: a randomised, controlled, double-
blind, phase 3, non-inferiority with nested superiority trial. Lancet
Infect Dis 15(2):161–171. doi:10.1016/S1473-3099(14)71018-7
6. Sader HS, Farrell DJ, Flamm RK, Jones RN (2016) Antimicrobial
activity of ceftaroline tested against Staphylococcus aureus from
surgical skin and skin structure infections in US medical centers.
Surg Infect 17(4):443–447. doi:10.1089/sur.2015.209
7. Fishovitz J, Rojas-AltuveA, Otero LH,DawleyM, Carrasco-López C,
Chang M, Hermoso JA, Mobashery S (2014) Disruption of allosteric
response as an unprecedented mechanism of resistance to antibiotics. J
Am Chem Soc 136(28):9814–9817. doi:10.1021/ja5030657
8. Kelley WL, Jousselin A, Barras C, Lelong E, Renzoni A (2015)
Missense mutations in PBP2A Affecting ceftaroline susceptibility
detected in epidemic hospital-acquired methicillin-resistant
Staphylococcus aureus clonotypes ST228 and ST247 in Western
Switzerland archived since 1998. Antimicrob Agents Chemother
59(4):1922–1930. doi:10.1128/AAC.04068-14
9. Sader HS, Flamm RK, Jones RN (2013) Antimicrobial activity of
ceftaroline and comparator agents tested against bacterial isolates
causing skin and soft tissue infections and community-acquired
respiratory tract infections isolated from the Asia-Pacific region
and South Africa (2010). Diagn Microbiol Infect Dis 76(1):61–
68. doi:10.1016/j.diagmicrobio.2013.01.005
10. Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm
DF, Bouchillon SK, Ambler JE (2015) In vitro activity of
ceftaroline against Staphylococcus aureus isolated in 2012 from
Asia-Pacific countries as part of the AWARE Surveillance
Program. Antimicrob Agents Chemother 60(1):343–347.
doi:10.1128/AAC.01867-15
11. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP,
Reiszner E, Sahm DF (2016) In vitro activity of ceftaroline against
bacterial pathogens isolated from skin and soft tissue infections in
Europe, Russia and Turkey in 2012: results from the Assessing
Worldwide Antimicrobial Resistance Evaluation (AWARE) sur-
veillance programme. J Antimicrob Chemother 71(1):162–169.
doi:10.1093/jac/dkv311
12. Zhang H, Xiao M, Kong F, O’Sullivan MV, Mao LL, Zhao HR,
Zhao Y, Wang H, Xu YC (2015) A multicentre study of meticillin-
resistant Staphylococcus aureus in acute bacterial skin and skin-
structure infections in China: susceptibility to ceftaroline and mo-
lecular epidemiology. Int J Antimicrob Agents 45(4):347–350.
doi:10.1016/j.ijantimicag.2014.12.014
13. Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK,
MusickWL, Rosato AE,Musser JM (2014) PBP2a mutations caus-
ing high-level Ceftaroline resistance in clinical methicillin-resistant
Staphylococcus aureus isolates. Antimicrob Agents Chemother
58(11):6668–6674. doi:10.1128/AAC.03622-14
14. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF
(2008) In vitro selection and characterization of ceftobiprole-
resistant methicillin-resistant Staphylococcus aureus. Antimicrob
Agents Chemother 52(6):2089–2096. doi:10.1128/AAC.01403-07
15. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri
SD (2014) Analysis of Staphylococcus aureus clinical isolates with
reduced susceptibility to ceftaroline: an epidemiological and struc-
tural perspective. J Antimicrob Chemother 69(8):2065–2075.
doi:10.1093/jac/dku114
16. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P,
Appelbaum PC, Kosowska-Shick K (2012) Characterization of
methicillin-resistant Staphylococcus aureus displaying increased
MICs of ceftaroline. J Antimicrob Chemother 67(6):1321–1324.
doi:10.1093/jac/dks069
17. Schaumburg F, Peters G, Alabi A, Becker K, Idelevich EA (2016)
Missense mutations of PBP2a are associated with reduced suscep-
tibility to ceftaroline and ceftobiprole in African MRSA. J
Antimicrob Chemother 71(1):41–44. doi:10.1093/jac/dkv325
18. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-López C,
Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D,
Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso
JA (2013) How allosteric control of Staphylococcus aureus peni-
cillin binding protein 2a enables methicillin resistance and physio-
logical function. Proc Natl Acad Sci U S A 110(42):16808–16813.
doi:10.1073/pnas.1300118110
Eur J Clin Microbiol Infect Dis (2017) 36:343–350 349
19. Fishovitz J, Hermoso JA, Chang M, Mobashery S (2014) Penicillin-
binding protein 2a of methicillin-resistant Staphylococcus aureus.
IUBMB Life 66(8):572–577. doi:10.1002/iub.1289
20. Fishovitz J, Taghizadeh N, Fisher JF, Chang M, Mobashery S
(2015) The Tipper–Strominger hypothesis and triggering of alloste-
ry in penicillin-binding protein 2a of methicillin-resistant
Staphylococcus aureus (MRSA). J Am Chem Soc 137(20):6500–
6505. doi:10.1021/jacs.5b01374
21. Lahiri SD, AlmRA (2016) Potential of Staphylococcus aureus isolates
carrying different PBP2a alleles to develop resistance to ceftaroline. J
Antimicrob Chemother 71(1):34–40. doi:10.1093/jac/dkv329
22. Lahiri SD, McLaughlin RE, Whiteaker JD, Ambler JE, Alm RA
(2015) Molecular characterization of MRSA isolates bracketing the
current EUCAST ceftaroline-susceptible breakpoint for
Staphylococcus aureus: the role of PBP2a in the activity of
ceftaroline. J Antimicrob Chemother 70(9):2488–2498.
doi:10.1093/jac/dkv131
23. Fernandez R, Paz LI, Rosato RR, Rosato AE (2014) Ceftaroline is
active against heteroresistant methicillin-resistant Staphylococcus
aureus clinical strains despite associated mutational mechanisms
and intermediate levels of resistance. Antimicrob Agents
Chemother 58(10):5736–5746. doi:10.1128/AAC.03019-14
24. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers
HF, Chiu CY (2016) Whole-genome sequencing of methicillin-
resistant Staphylococcus aureus resistant to fifth-generation cepha-
losporins reveals potential non-mecA mechanisms of resistance.
PLoS One 11(2), e0149541. doi:10.1371/journal.pone.0149541
25. Strommenger B, Layer F, Klare I, Werner G (2015) Pre-use suscep-
tibility to ceftaroline in clinical Staphylococcus aureus isolates from
Germany: is there a non-susceptible pool to be selected? PLoS One
10(5), e0125864. doi:10.1371/journal.pone.0125864
26. Fankhauser C, Schrenzel J, Francois P, Pittet D, Harbarth S (2015)
Secular trends of methicillin-resistant Staphylococcus aureus
(MRSA) at Geneva University Hospitals (HUG) over a 14-year
period. In: Antimicrobial Resistance and Infection Control:
Abstracts from the 3rd International Conference on Prevention
and Infection Control (ICPIC 2015), Geneva, Switzerland,
June 2015. Abstract 09
27. Renzoni A, Huggler E, Kelley WL, Lew D, Vaudaux P (2009)
Increased uptake and improved intracellular survival of a
te icoplanin-res is tant mutant of methic i l l in-resis tant
Staphylococcus aureus in non-professional phagocytes.
Chemotherapy 55(3):183–188. doi:10.1159/000215304
28. Francois P, Huyghe A, Charbonnier Y, Bento M, Herzig S, Topolski I,
Fleury B, Lew D, Vaudaux P, Harbarth S, van Leeuwen W, van
BelkumA,BlancDS, Pittet D, Schrenzel J (2005)Use of an automated
multiple-locus, variable-number tandem repeat-based method for rapid
and high-throughput genotyping of Staphylococcus aureus isolates. J
Clin Microbiol 43(7):3346–3355. doi:10.1128/JCM.43.7.3346-
3355.2005
29. Koessler T, Francois P, Charbonnier Y,HuygheA, BentoM,Dharan S,
Renzi G, Lew D, Harbarth S, Pittet D, Schrenzel J (2006) Use of
oligoarrays for characterization of community-onset methicillin-resis-
tant Staphylococcus aureus. J Clin Microbiol 44(3):1040–1048.
doi:10.1128/JCM.44.3.1040-1048.2006
30. Campanile F, Bongiorno D, Borbone S, Stefani S (2009) Hospital-
associated methicillin-resistant Staphylococcus aureus (HA-
MRSA) in Italy. Ann Clin Microbiol Antimicrob 8:22.
doi:10.1186/1476-0711-8-22
31. Vaudaux P, Huggler E, Bernard L, Ferry T, Renzoni A, Lew DP
(2010) Underestimation of vancomycin and teicoplanin MICs by
broth microdilution leads to underdetection of glycopeptide-
intermediate isolates of Staphylococcus aureus. Antimicrob
Agents Chemother 54(9):3861–3870. doi:10.1128/AAC.00269-10
32. Francois P, Harbarth S, Huyghe A, Renzi G, Bento M, Gervaix A,
Pittet D, Schrenzel J (2008) Methicillin-resistant Staphylococcus
aureus, Geneva, Switzerland, 1993–2005. Emerg Infect Dis
14(2):304–307. doi:10.3201/eid1402.070229
33. Jousselin A, Renzoni A, Andrey DO, Monod A, Lew DP, Kelley
WL (2012) The posttranslocational chaperone lipoprotein PrsA is
involved in both glycopeptide and oxacillin resistance in
Staphylococcus aureus. Antimicrob Agents Chemother 56(7):
3629–3640. doi:10.1128/AAC.06264-11
34. Jousselin A, Manzano C, Biette A, Reed P, Pinho MG, Rosato AE,
Kelley WL, Renzoni A (2015) The Staphylococcus aureus chaper-
one PrsA is a new auxiliary factor of oxacillin resistance affecting
penicillin-binding protein 2A. Antimicrob Agents Chemother
60(3):1656–1666. doi:10.1128/AAC.02333-15
350 Eur J Clin Microbiol Infect Dis (2017) 36:343–350
